ジョンソン・エンド・ジョンソンがシーズ・ホールディングスの買収を完了
ジョンソン・エンド・ジョンソンがシーズ・ホールディングスの買収を完了
AsiaNet 77113 (0092)
【ニューブランズウィック(米ニュージャージー州)2019年1月17日PR Newswire=共同通信JBN】
*買収でJ&Jの科学ベースのダーマコスメティック美容製品のポートフォリオが拡大
ジョンソン・エンド・ジョンソン(Johnson & Johnson 、NYSE: JNJ)は17日、株式会社シーズ・ホールディングス(Ci:z Holdings Co., Ltd. 、TYO: 4924、同社)に対する総額約2300億円の買収を完了したと発表した。買収は同社の公開株を1株5900円で全額現金による買い取りを含む一連の取引を通じて終えた。ジョンソン・エンド・ジョンソンは公開買い付けに応じなかった残りの同社株について、日本の法律の下での株式併合によって2019年前半に取得し、同社の東京証券取引所の上場を廃止する適切な行動を取る計画。
Logo - https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg
スキンケア製品ラインの「ドクターシーラボ(Dr.Ci:Labo)」や「ラボラボ(Labo Labo)」、「ジェノマー(Genomer)」を販売する同社は今後、ジョンソン・エンド・ジョンソンのコンシューマー企業グループ傘下に入る。
ジョンソン・エンド・ジョンソン・コンシューマー(Johnson & Johnson Consumer)のワールドワイド会長であるホルヘ・メスキタ氏は「ドクターシーラボとラボラボ、ジェノマーの取得で、われわれの拡大する化粧品の品ぞろえは、ユニークなダーマコスメティック・イノベーションを伴って強化される。この重要な取引の完了をとてもうれしく思い、世界中の健康と美容の消費者に、効能があって、科学に基づくスキンケア製品を届けられるのを楽しみにしている」と述べた。
この買収に伴う1株利益への影響は、ジョンソン・エンド・ジョンソンが2018年第4四半期決算の記者発表に合わせて公表する2019年のガイダンスで触れられる。
▽ジョンソン・エンド・ジョンソン(Johnson & Johnson)について
ジョンソン・エンド・ジョンソンは、良好な健康が活力のある人生、地域社会の繁栄、将来の発展の基盤であると信じる。だからこそ、同社は130年以上もの間、あらゆる年代、あらゆる人生段階の人々の健康を支えようと努めてきた。今日、世界最大級で広範な拠点を有するヘルスケア企業としての強みを最大限に生かし、世界中の誰もが、どこにいても、心身の健康と健全な環境を享受することができるよう、同社は適正な価格でヘルスケアにアクセスできる、より健全な社会の実現に向けて努力している。同社は、その思いと科学、創意工夫を1つにして、人類のために健康の流れを根本から変えようとしている。
ソース:Johnson & Johnson
▽メディア問い合わせ先
Ernie Knewitz
+1 (732) 524-6623, +1 (917) 697-2318
(M), eknewitz@its.jnj.com
Mel Tyndale-Biscoe
+65 8798 2475 (Singapore)
MTYNDALE@its.jnj.com
Donna Lorenson
+1 (410) 258-8571
dlorens@its.jnj.com
▽投資家問い合わせ先
Lisa Romanko
+1 (732) 524-2034
LRomank3@its.jnj.com
Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.
PR77113
NEW BRUNSWICK, New Jersey, Jan. 17, 2019 /PRNewswire=KYODO JBN/ --
--Acquisition Expands J&J's Portfolio of Science-based Dermocosmetic Beauty
Products
Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition
of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") for a total purchase
price of approximately JPY 230 billion. The acquisition was completed through a
series of transactions that included an all-cash tender offer to acquire
publicly held shares of the Company for JPY 5,900 per share. Johnson & Johnson
plans to acquire the remaining shares of the Company that were not tendered in
the tender offer through a share consolidation under Japanese law during the
first half of 2019 and take appropriate actions to delist the Company from the
Tokyo Stock Exchange.
Logo - https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg
The Company, which markets the DR. CI:LABO, LABO LABO and GENOMER line of
skincare products, will now become part of the Johnson & Johnson Family of
Consumer Companies.
"The addition of DR. CI:LABO, LABO LABO and GENOMER to our franchise
strengthens our growing beauty portfolio with unique dermocosmetic innovation,"
said Jorge Mesquita, Worldwide Chairman, Johnson & Johnson Consumer. "We are
very pleased to complete this important transaction and look forward to
bringing efficacious, science-backed skincare products to our health and beauty
consumers around the world."
Any EPS impact of the transaction will be included in the 2019 guidance
provided on Johnson & Johnson's Q4 2018 earnings call.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant
lives, thriving communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every stage of life.
Today, as the world's largest and most broadly-based health care company, we
are committed to using our reach and size for good. We strive to improve access
and affordability, create healthier communities, and put a healthy mind, body
and environment within reach of everyone, everywhere. We are blending our
heart, science and ingenuity to profoundly change the trajectory of health for
humanity.
NOTE CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995 regarding the potential
transaction between Johnson & Johnson and the Company. The reader is cautioned
not to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize, actual
results could vary materially from the expectations and projections of Johnson
& Johnson and the Company. Risks and uncertainties include, but are not limited
to: the satisfaction of closing conditions for the transaction, including the
receipt of regulatory approvals for the transaction; the tender of the
requisite amount of the outstanding shares of the Company; the possibility that
the transaction will not be completed in the expected timeframe or at all; the
potential that the expected benefits and opportunities of the transaction, if
completed, may not be realized or may take longer to realize than expected;
uncertainty of commercial success for new and existing products; manufacturing
difficulties and delays; economic conditions, including currency exchange and
interest rate fluctuations; competition, including technological advances, new
products and patents attained by competitors; changes to applicable laws and
regulations, including tax laws and domestic and foreign health care reforms;
adverse litigation or government action; changes in behavior and spending
patterns or financial distress of purchasers of health care products and
services; and trends toward health care cost containment. In addition, if and
when the transaction is consummated, there will be risks and uncertainties
related to the ability of the Johnson & Johnson Family of Companies to
successfully integrate the products, employees and operations of the Company,
as well as the ability to ensure continued performance or market growth of the
Company's products. A further list and description of these risks,
uncertainties and other factors can be found in Johnson & Johnson's publicly
available filings with the U.S. Securities and Exchange Commission. Copies of
these filings, as well as subsequent filings, are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson &
Johnson does not undertake to update any forward-looking statement as a result
of new information or future events or developments.
SOURCE: Johnson & Johnson
CONTACT: Media Contacts: Ernie Knewitz, +1 (732) 524-6623, +1 (917) 697-2318
(M), eknewitz@its.jnj.com; Mel Tyndale-Biscoe, +65 8798 2475 (Singapore),
MTYNDALE@its.jnj.com; Donna Lorenson, +1 (410) 258-8571, dlorens@its.jnj.com;
Investor Contact: Lisa Romanko, +1 (732) 524-2034, LRomank3@its.jnj.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。